Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells 55,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the completion of the sale, the chief executive officer now directly owns 331,017 shares of the company’s stock, valued at $5,273,100.81. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Saurabh Saha also recently made the following trade(s):

• On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.77, for a total transaction of $867,350.00.
• On Friday, December 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $17.44, for a total transaction of $959,200.00.
• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.23, for a total transaction of $5,450.77.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.24, for a total transaction of $30,479.04.

Centessa Pharmaceuticals Stock Up 5.3 %

Shares of CNTA traded up $0.84 during trading hours on Thursday, reaching $16.75. The company’s stock had a trading volume of 762,948 shares, compared to its average volume of 793,520. The firm has a market cap of $2.21 billion, a price-to-earnings ratio of -10.95 and a beta of 1.53. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average of $16.71 and a two-hundred day moving average of $15.78.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock. Guggenheim restated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Buy” and an average price target of $25.83.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of large investors have recently made changes to their positions in CNTA. Janus Henderson Group PLC grew its stake in shares of Centessa Pharmaceuticals by 279.2% in the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after buying an additional 3,614,623 shares in the last quarter. Foresite Capital Management VI LLC bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $20,994,000. Franklin Resources Inc. grew its stake in shares of Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after buying an additional 1,145,823 shares in the last quarter. Point72 Asset Management L.P. grew its stake in shares of Centessa Pharmaceuticals by 54.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock valued at $43,423,000 after buying an additional 953,659 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in shares of Centessa Pharmaceuticals by 22.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after buying an additional 924,027 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.